Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the LillyMedical.com website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.com.

  1. Medical Information Right
  2. Diabetes Right
  3. Basaglar (insulin glargine) injection Right
  4. Do patients on Basaglar® (insulin glargine) achieve an HbA1c of <7%?
Search Basaglar (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Basaglar ® (insulin glargine) injection

100 units/mL

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

Do patients on Basaglar® (insulin glargine) achieve an HbA1c of <7%?

In patients with type 1 diabetes treated with Basaglar, 34.5% achieved an HbA1c <7% at 24 weeks while 48.8% with type 2 diabetes achieved an HbA1c <7%. The percentages were similar to those achieved with comparator insulin glargine 100 units/mL products.

US_cFAQ_BIV019_LESS_THAN_7_HBA1C
US_cFAQ_BIV019_LESS_THAN_7_HBA1C
en-US

Basaglar Clinical Studies: Type 1 or Type 2 Diabetes

Adult patients with inadequately controlled type 1 diabetes participated in a 24-week, open‑label, active-controlled study with a 28-week extension to evaluate the glucose lowering effect of once-daily Basaglar® (insulin glargine) 100 units/mL compared with that of once-daily administration of another insulin glargine 100 units/mL product or a non-US-approved insulin glargine 100 units/mL product, both in combination with mealtime insulin lispro.1

Adult patients with type 2 diabetes participated in a double-blind, active-controlled study to evaluate the glucose lowering effect of once-daily Basaglar plus oral antihyperglycemic medications (OAMs) compared with that of another insulin glargine 100 units/mL product or a non‑US‑approved insulin glargine 100 units/mL product administered once daily along with OAMs. Patients were

  • insulin naïve (~60%) and had failed to achieve adequate glycemic control on at least 2 OAMs, or
  • already on another insulin glargine 100 units/mL product or a non‑US‑approved insulin glargine 100 units/mL product along with at least 2 OAMs with adequate or inadequate glycemic control (~40%).1

HbA1c Less Than 7%

At 24 weeks, the percentage of patients who achieved a glycated hemoglobin (HbA1c) of <7% was similar between treatment groups (Achievement of HbA1c Less Than 7% at 24 Weeks in Phase 3 Clinical Studies of Basaglar).1

Achievement of HbA1c Less Than 7% at 24 Weeks in Phase 3 Clinical Studies of Basaglar1

HbA1c

Type 1 Diabetes

Type 2 Diabetes

Basaglar + Insulin Lispro
(n=268)a

Comparator Insulin Glargine 100 Units/mL Productsb + Insulin Lispro
(n=267)

Basaglar + OAMs
(n=376)c

Comparator Insulin Glargine 100 Units/mL Productsb + OAMs
(n=380)

Percentage of patients achieving HbA1c <7%d

34.5

32.2

48.8

52.5

Abbreviations: Basaglar = Basaglar® (insulin glargine) 100 units/mL; HbA1c = glycated hemoglobin; OAMs = oral antihyperglycemic medications.

aIncludes 1 patient randomized to the Basaglar treatment group who was not included in the full analysis set.

bAnother insulin glargine 100 units/mL product and a non-US-approved insulin glargine 100 units/mL product.

cA total of 3 patients randomized to the Basaglar treatment group did not receive study drug and were not included in the full analysis set.

dResults were calculated based on the number of patients in the full analysis set using their last observed postbaseline value of HbA1c. Observed HbA1c data at 24 weeks were available from 256 patients (95.5%) in the Basaglar treatment group and 258 patients (96.6%) in the comparator insulin glargine 100 units/mL treatment group in patients with type 1 diabetes and from 331 patients (88%) in the Basaglar treatment group and 329 patients (87%) in the comparator insulin glargine 100 units/mL treatment group in patients with type 2 diabetes.

Enclosed Prescribing Information

BASAGLAR® (insulin glargine) injection, for subcutaneous use, Lilly

HUMALOG® (insulin lispro injection), for subcutaneous or intravenous use, Lilly

Reference

1Basaglar [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.

Date of Last Review: October 28, 2021

Additional related information:

  • BASAGLAR® (insulin glargine injection) 100 Units/mL: Use in Patients With Type 1 Diabetes Mellitus
  • BASAGLAR® (insulin glargine injection) 100 Units/mL: Use in Patients With Type 2 Diabetes Mellitus
Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.17 02/2023 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2023. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    facebook twitter linkedin
    visit www.phactmi.org
    Behringer Ingelheim partner logo and Lilly logo Behringer Ingelheim partner logo and Lilly logo